Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TTPA | P49638 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927456 | 0.87 | PTGS1 (0.65) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2059486 | 0.87 | PTGS1 (0.65) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL17289303 | 0.84 | PTGS1 (0.58) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL1928208 | 0.84 | PTGS1 (0.78) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL3226 | 0.84 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| (R)-Trolox SCHEMBL615168 | 0.84 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL8270579 | 0.84 | PTGS1 (0.78) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL1651402 | 0.84 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL1927837 | 0.84 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL16247633 | 0.84 | PTGS1 (0.78) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733642-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3733642-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3456707-B1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3456707-A1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BioElectron Technology Corporation (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10167251-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| EP-3018122-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-10 | — | — | EP | disclosed |
| US-9546132-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-3018122-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | Edison Pharmaceuticals, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20160075638-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2016-03-17 | — | — | US | disclosed |
| EP-2220030-B1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9169196-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2013-10-31 | — | — | US | disclosed |
| US-8519001-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-7968746-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2791/4885PTGS2 2540/4885CYP1A2 3891/4885 |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20160075638-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-10167251-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | PTGS1 2860/4885PTGS2 2651/4885CYP1A2 3880/4885 |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | PTGS1 2791/4885PTGS2 2540/4885CYP1A2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.